EDWARD K BARNES
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology NASHVILLE, TN NPI 1770538738
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology TN NOVARTIS PHARMACEUTICALS CORPORATION All categories
General Payments — all program years on this page
$2,473.21
- Category: General Payments
- Program years: PY2018–2024
- Record count: 110
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $1,029.40 across 41 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,009.40 | 40 |
| Education | $20.00 | 1 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| NOVARTIS PHARMACEUTICALS CORPORATION | $85.91 | 3 |
| Merck Sharp & Dohme Corporation | $81.31 | 3 |
| Acerta Pharma LLC | $63.63 | 2 |
| Janssen Biotech, Inc. | $58.94 | 2 |
| Gilead Sciences, Inc. | $51.58 | 2 |
| AVEO Pharmaceuticals, Inc. | $47.65 | 2 |
| GlaxoSmithKline, LLC. | $46.79 | 2 |
| ABBVIE INC. | $44.21 | 2 |
| Exelixis Inc. | $42.32 | 2 |
| Daiichi Sankyo Inc. | $41.79 | 2 |
| E.R. Squibb & Sons, L.L.C. | $40.53 | 2 |
| Celgene Corporation | $40.50 | 2 |
| GENZYME CORPORATION | $38.19 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $37.55 | 2 |
| Deciphera Pharmaceuticals Inc. | $35.95 | 1 |
| Ipsen Biopharmaceuticals, Inc | $34.45 | 1 |
| JAZZ PHARMACEUTICALS INC. | $34.21 | 1 |
| Regeneron Healthcare Solutions, Inc. | $32.58 | 1 |
| ARRAY BIOPHARMA INC | $25.75 | 1 |
| Genentech USA, Inc. | $25.38 | 1 |
| EISAI INC. | $23.68 | 1 |
| Stemline Therapeutics Inc. | $22.67 | 1 |
| Incyte Corporation | $21.16 | 1 |
| PharmaEssentia USA Corporation | $18.64 | 1 |
| Pharmacosmos Therapeutics Inc. | $17.19 | 1 |
| BeiGene USA, Inc. | $16.84 | 1 |
By program year
Records — PY2024 (41)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.